What is Merck & Co.'s expected EPS for Q2 2026?

Analysts expect Merck & Co. (MRK) to report consensus EPS of approximately $-0.25 for Q2 2026. Estimates range from $-0.36 to $-0.0258.

What revenue do analysts expect for Merck & Co. in Q2 2026?

The consensus revenue forecast for Merck & Co. (MRK) in Q2 2026 is approximately $16.4B. Forecasts range from $16.2B to $16.6B.

How many analysts cover Merck & Co.?

8 analysts contribute to the Merck & Co. (MRK) Q2 2026 consensus estimate.

Has Merck & Co. beaten earnings estimates recently?

Merck & Co. beat analyst EPS estimates in 2 of the last 2 quarters. Merck & Co. beat revenue estimates in 2 of 2. In the most recent quarter (Q1 2026), Merck & Co. EPS beat by 13.2% and revenue beat by 2.8%.

When does Merck & Co. report Q2 2026 earnings?

Merck & Co. (MRK) is expected to report Q2 2026 earnings on August 4, 2026 before market open.

MRK Q2 2026 earnings estimate

Consensus EPS · Q2 2026

-$0.25

Consensus revenue · Q2 2026

$16.4B

Analysts

Expected report

Aug 4, 2026

Before open

Upcoming earnings

Locks in 11 days 4 hours · BMO: Locks 8:00 PM ET previous day

Revenue$16.4B$16.2B – $16.6B

EPS-$0.25-$0.36 – -$0.03

What to watch

Analyst ratings: Mixed

Make your prediction

Analyst consensus

Based on estimates from 8 analysts.

Metric	Low	Consensus	High
Revenue	$16.2B	$16.4B	$16.6B
EPS	-$0.36	-$0.25	-$0.03
EBITDA	$8.3B	$8.4B	$8.5B
EBIT	$6.5B	$6.6B	$6.7B
Net income	-$984.7M	-$711.2M	-$574.4M

Revenue$16.4B
EPS-$0.25
EBITDA$8.4B
EBIT$6.6B
Net income-$711.2M

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	$16.3B	$15.8B	+2.8%	-$1.28	-$1.47	+13.2%
Q4 2025	$16.4B	$16.2B	+1.2%	$2.04	$2.01	+1.4%

Q1 2026+2.8%+13.2%
Q4 2025+1.2%+1.4%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Grade A — Strong upward revisions

Metric	Now	30d ago	60d ago	90d ago	30d Δ
Revenue	$16.4B	$16.4B	—	—	+0.3%
EPS	$2.14	$2.11	—	—	+1.6%

2 revised up (30d)0 revised down (30d)

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for Merck & Co. (MRK) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 5 analysts.

Low: $100.00
Consensus: $136.33
Median: $142.00
High: $155.00
Current: $127.47
Upside: +7.0%

Upside calculated vs most recent trading price of $127.47.

Analyst ratings

Consensus: Buy — based on 37 analyst ratings.

Buy 25Hold 11Sell 1

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Jul 13, 2026	JP Morgan	maintain	Overweight	Overweight
Jul 13, 2026	Guggenheim	maintain	Buy	Buy
Jul 13, 2026	BMO Capital	maintain	Outperform	Outperform
Jul 9, 2026	Morgan Stanley	maintain	Equal Weight	Equal Weight
Jul 8, 2026	Wells Fargo	maintain	Overweight	Overweight
Jul 8, 2026	RBC Capital	maintain	Outperform	Outperform
Jul 6, 2026	Cantor Fitzgerald	maintain	Neutral	Neutral
Jun 30, 2026	Scotiabank	maintain	Sector Outperform	Sector Outperform
Jun 30, 2026	B of A Securities	maintain	Buy	Buy
May 1, 2026	Wells Fargo	maintain	Overweight	Overweight

Jul 13, 2026JP MorganOverweight
Jul 13, 2026GuggenheimBuy
Jul 13, 2026BMO CapitalOutperform
Jul 9, 2026Morgan StanleyEqual Weight
Jul 8, 2026Wells FargoOverweight
Jul 8, 2026RBC CapitalOutperform
Jul 6, 2026Cantor FitzgeraldNeutral
Jun 30, 2026ScotiabankSector Outperform
Jun 30, 2026B of A SecuritiesBuy
May 1, 2026Wells FargoOverweight

Frequently asked questions

Merck & Co. (MRK) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

MRK Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation